CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma

Blood

Volumn 105, Issue 4, 2005, Pages 1417-1423

  Marcus, Robert ^a   Imrie, Kevin ^b   Belch, Andrew ^b   Cunningham, David ^b   Flores, Eduardo ^b   Catalano, John ^b   Solal Celigny, Philippe ^b   Offner, Fritz ^b   Walewski, Jan ^b   Raposo, Joäo ^b   Jack, Andrew ^b   Smith, Paul ^b  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; ADVANCED CANCER; ARTICLE; BACKACHE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FOLLICULAR LYMPHOMA; GASTROINTESTINAL SYMPTOM; HUMAN; MALE; MULTICENTER STUDY; NEUROLOGIC DISEASE; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SURVIVAL RATE; SURVIVAL TIME;

EID: 13244270361     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-08-3175     Document Type: Article

References (38)

1. The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation ot the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood. 1997;89:3909-3918.
2. Horning SJ. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol. 1993;20;75-83.
3. Solal-Celigny PH. Management of histologically indolent non-Hodgkin's lymphomas. Baillière's Clin Hematol. 1996;9:669-687.
4. Aisenberg AC. Coherent view of non-Hodgkin's lymphoma [review]. Clin Oncol. 1995;13:2656-2675.
5. Horning SJ. Treatment approaches to the low-grade lymphomas. Blood. 1994;83:881-884.
6. Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med. 1984;311:1471-1475.
7. Ardeshna KM, Smith P, Norton A, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet. 2003;362:516-522.
8. Lister TA. The management of follicular lymphoma. Ann Oncol. 1991;2:131-135.
9. Kennedy BJ, Bloomfield CD, Kiang DT, et al. Combination versus successive single agent chemotherapy in lymphocytic lymphoma. Cancer. 1978;41:23-30.
10. Portlock CS, Rosenberg SA. Combination chemotherapy with cyclophosphamide, vincristine and prednisone in advanced non-Hodgkin's lymphoma. Cancer. 1976;37:1275-1280.
11. Jones SE, Rosenberg SA, Kaplan HS, et al. Non-Hodgkin's lymphoma II. Single agent chemotherapy. Cancer. 1972;30:31-37.
12. Peterson BA, Petroni GR, Frizzera G, et al. Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B. J Clin Oncol. 2003;21:5-15.
13. Kimby E, Bjorkholm M, Gahrton G, et al. Chlorambucil/prednisolone vs. CHOP in symptomatic low-grade non-Hodgkin's lymphomas: a randomized trial from the Lymphoma Group of Central Sweden. Ann Oncol. 1994;5:567-571.
14. Solal-Celigny P, Lepage E, Brousse N, et al. Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial. J Clin Oncol. 1998;16:2332-2338.
15. Hagenbeek A, Eghbali H, Monfardini S, et al. Fludarabine compared with CVP chemotherapy in newly diagnosed patients with stages III and IV low grade malignant non-Hodgkin's lymphoma. Final analysis of a prospective randomized phase III Intergroup study in 381 patients [abstract]. Blood. 2001;98:11 a. Abstract no. 3501.
16. Arranz R, Garcia Alfonso P, Sobrino P, et al. Role of Interferon alfa-2b in the induction and maintenance treatment of low-grade non-Hodgkin's lymphoma: results from a prospective multicenter trial with double randomization. J Clin Oncol. 1998;16:1538-1546.
17. Hagenbeek A, Carde P, Meerwaldt JH, et al. Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol. 1998;16:41-47.
18. Sebban C, Belanger C, Brousse N, et al. Comparison of CHVP + interferon with CHOP followed by autologous stem cell transplantation with a TBI conditioning regimen in untreated patients with high tumor burden follicular lymphoma: results of the randomized GELF94 Trial (GELA Study Group) [abstract]. Blood. 2003;102:11a. Abstract no. 354.
19. Velasquez WS, Lew D, Grogan TM, et al. Combination of fludarabine and mitoxantrone in untreated stages III and IV low-grade lymphoma. J Clin Oncol. 2003;21:1996-2003.
20. McLaughlin P, Rodriguez MA, Hagemeister FB, et al. Stage IV indolent lymphoma: A randomized study of concurrent vs. sequential use of FND chemotherapy (fludarabine, mitoxantrone, dexamethasone) and rituximab (R) monoclonal antibody therapy, with interferon maintenance. Proc Am Soc Clin Oncol. 2003;22:564.
21. Cerny T, Borisch B, Introna M, Johnson P, Rose AL. Mechanism of action of rituximab. Anticancer Drugs. 2002;13:S3-S10.
22. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825-2833.
23. Colombat P, Salles G, Brousse N, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood. 2001;97:101-106.
24. Demidem A, Lam T, Alas S, Hariharan K, Hanna N, Bonavida B. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm. 1997;12:177-186.
25. Alas S, Emmanouilides C, Bonavida B. Inhibition of inlerleukin 10 by rituximab results in downregulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clin Cancer Res. 2001;7:709-723.
26. Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti CD-20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol. 1999;17:268-276.
27. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329:987-994.
28. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma. J Clin Oncol. 1999;17:1244-1253.
29. Wittes RE. Common toxicity criteria for cancer clinical trials, version 1.0. In: MacDonald JS, Haller DG, Mayer RJ, eds. Manual of Oncologic Therapeutics. 3rd ed. Philadelphia, PA: Lippincott; 1995:445-448.
30. Unterhalt M, Hermann R, Tiemann M, et al. Prednimustine, mitoxantrone (PmM), vs. cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma. Leukemia. 1996;10;836-843.
31. Teodorovic I, Pittaluga S, Kluin Nelemans JC, et al. Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. J Oncol. 1995;13:2819-2826.
32. Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104:1258-1265.
33. Coiffier B, Lepage E, Brière J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235-242.
34. Haase-Statz S, Smalley RV. Role of interferon-alfa in NHL: still controversial? Oncology. 1999;13:1147-1159; discussion 1159-1160, 1163.
35. Solal-Celigny P, Lepage E, Brousse N, et al. Recombinant Interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d'Etude des Lymphomes de l'Adulte. N Engl J Med. 1993;329:1608-1614.
36. Hainsworth JD, Litchy S, Morrissey L, Yardley DA, Greco FA. Rituximab as first-line and maintenance therapy for indolent non-Hodgkin's lymphoma (NHL): long-term follow-up of a Minnie Pearl Cancer Research Network Phase II trials. Blood. 2003;102:11 a. Abstract no. 1496.
37. Hochster HS, Weller E, Ryan T, et al. Results of E1496: A phase III trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL) [abstract]. Proc Am Soc Clin Oncol. 2004;23:556.
38. Hiddemann W, Dreyling MH, Forstpointner R, et al. Combined immuno-chemotherapy (R-CHOP) significantly improves lime to treatment failure in first line therapy of follicular lymphoma. Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG) [abstract]. Blood. 2003;102:11a. Abstract no. 352.